ABSI Absci Corp
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1672688 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-47.2%
TTM net income YoY-9.7%
TTM EPS YoY13.2%
Revenue 3-yr CAGR-40.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,812.3%
Net margin-8,451.3%
FCF margin-7,562.7%
EBITDA margin-8,076.6%
Returns
ROE-58.6%
ROA-51.9%
ROIC (approx.)-53.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio9.64x
Interest coverage-2,569.39x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue-4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.80M | $4.53M |
| R&D expense | $81.42M | $63.86M |
| SG&A expense | $35.06M | $36.17M |
| Operating income | -$120.32M | -$108.89M |
| Interest expense | $209,000 | $565,000 |
| Pretax income | -$115.11M | -$103.04M |
| Income tax | $69,000 | $70,000 |
| Net income | -$115.18M | -$103.11M |
| EBITDA | -$108.58M | -$95.50M |
| EPS (basic) | -0.84 | -0.94 |
| EPS (diluted) | -0.84 | -0.94 |
| Weighted avg. shares (diluted) | 136.78M | 110.24M |
| Balance sheet | ||
| Cash & equivalents | $20.02M | $58.21M |
| Short-term investments | $124.27M | $71.21M |
| Receivables | — | $0 |
| Current assets | $149.57M | $133.83M |
| PP&E, net | $20.86M | $29.17M |
| Intangibles | $41.51M | $44.88M |
| Total assets | $216.30M | $213.61M |
| Current liabilities | $22.77M | $28.66M |
| Long-term debt | — | $3.99M |
| Total debt | — | $3.99M |
| Total liabilities | $26.85M | $34.48M |
| Shareholders' equity | $189.45M | $179.13M |
| Net debt | — | -$54.22M |
| Shares outstanding | — | 115.36M |
| Cash flow statement | ||
| Operating cash flow | -$92.92M | -$72.40M |
| Capital expenditure | $1.11M | $404,000 |
| Free cash flow | -$94.03M | -$72.81M |
| Investing cash flow | -$50.16M | -$41.58M |
| Financing cash flow | $105.95M | $82.53M |
| Depreciation & amortization | $11.74M | $13.39M |
| Stock-based compensation | $18.32M | $19.45M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.